CHMP adopts positive opinion for aflibercept (Eylea) solution for injection for the treatment of wet age-related macular degeneration

Source: EMA
Area: News
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product aflibercept (Eylea), 40 mg/mL solution for injection, intended for the treatment of neovascular (wet) age-related macular degeneration (AMD).   Aflibercept, an antineovascularisation agent, acts by binding and inhibiting VEGF-A (Vascular endothelial growth factor-A). A pharmacovigilance plan for Eylea will be implemented as part of the marketing authorisation.   Detailed recommendations for the use of this product will be described in the summary of product characteristics (SmPC), which will be published in the European public assessment report (EPAR) after the marketing authorisation has been granted by the European Commission.